Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §

  title={Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §},
  author={Juliane Winkelmann and Richard P. Allen and Birgit H{\"o}gl and Yuichi Inoue and Wolfgang Hermann Oertel and Aaro V. Salminen and John W. Winkelman and Claudia Trenkwalder and Cristina Sampaio},
  journal={Movement Disorders},
The objective of the current review was to update the previous evidence‐based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise… 

Restless Legs Syndrome and Other Movement Disorders of Sleep—Treatment Update

With emerging evidence of augmentation being a side effect specific to dopaminergic treatment, gabapentinoids are considered a safer option as initial treatment of restless legs syndrome, and in severe refractory RLS, oxycodone-naloxone can be used.

The Efficacy and Safety of Pharmacological Treatments for Restless Legs Syndrome: Systemic Review and Network Meta-Analysis

The pooled results showed that, compared with placebo, only levodopa is inefficient to relieve symptoms of RLS, and Alpha-2-delta ligands and DAs are favorable choices for both primary and secondary RLS because of their significant efficacy and good tolerability.

Comparative efficacy and acceptability of treatments for restless legs syndrome in end-stage renal disease: a systematic review and network meta-analysis.

  • Chien-Wei HuangMin-Jing Lee Pao-Yen Lin
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2019
This network meta-analysis supports that gabapentin is the most effective treatment for RLS in ESRD patients and exercise plus dopamine agonist is a favorable combination therapy concerning side effects.

Update on Restless Legs Syndrome: from Mechanisms to Treatment

The understanding of disease pathophysiology has improved, specifically regarding iron regulation in the brain and the role of other pathways such as opioid signaling and brain and spinal cord circuitry may play in RLS/WED.

An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges

This review provides an update regarding the treatment of RLS/WED with particular attention to future challenges for its management, and reviewed a large variety of treatments studied in clinical trials and supported by the most updated guidelines.

Challenges in the Treatment of Restless Legs Syndrome: A Case Report

This report demonstrates a challenging case of RLS in the setting of psychiatric comorbidities, development of augmentation, and polypharmacy in a 69-year-old Caucasian gentleman with bipolar disorder type I, unspecified anxiety disorder, obstructive sleep apnea, and treatment-refractory RLS.

Therapies for Restless Legs in Parkinson's Disease.

The treatment of RLS in PD consists in adaptation of dopaminergic treatment and introduction of alpha-2-delta ligands and, in refractory cases, of opioids or deep brain stimulation.

Reply to: A note on rotigotine for restless legs syndrome after renal transplantation

The notion that rotigotine, even at 1-2 mg per day may constitute an efficacious and safe option to treat RLS in RT patients is supported, albeit small, by a retrospectively analyzed 7 female RT patients.

Therapies for Restless Legs in Parkinson’s Disease

The aim of this article was to review the options and particularities of the treatment of restless legs syndrome (RLS) in Parkinson’s disease (PD), finding that arrangements linked to the peculiar population and pathology of PD are required.



Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study

The benefits of pregabalin on sensory and motor symptoms in restless legs syndrome (RLS) and its utilization in health research is overstated because the recommendation of placebo in clinical trials is based on efficacy, shorter study duration, and lower cost.

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial.

This study confirms that ropinirole improves RLS symptoms and subjective measures of sleep, quality of life, and anxiety and that it is generally well tolerated.

Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, double-blinded, sham-controlled trial.

PCDs resulted in clinically significant improvements in symptoms of RLS in comparison to the use of sham devices and may be an effective adjunctive or alternative therapy for RLS.

Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.

Ropinirole improves restless legs syndrome compared with placebo, with benefits apparent by week 1, and is generally well tolerated.

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi‐center, randomized, active controlled trial

This first large‐scale double‐blind, randomly assigned study in RLS showed superior efficacy of cabergoline versus levodopa after a 30‐week long‐term therapy and Tolerability was found more favorable withlevodopa than with Cabergoline.

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12‐week, double‐blind, randomized, parallel‐group, placebo‐controlled study

Ropinirole improves symptoms, associated sleep disturbance, and QoL of RLS patients and is generally well tolerated.